Loading...
Market
Story
Pfizer's RSV Vaccine Shows Strong Results in Immunocompromised Adults
Aug 12, 2024, 11:00 AM
Pfizer announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has demonstrated a strong immune response in a late-stage study involving immunocompromised adults aged 18 and older. The study showed that a single dose of the vaccine produced robust antibodies against RSV-A and RSV-B, indicating potential benefits for adults at risk of severe RSV-related illness. The top-line results highlight the vaccine's efficacy in generating an immune response in this vulnerable population.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
USA • 25%
EU • 25%
Canada • 25%
Other • 25%
